Development of a Highly Cardioselective Ultra Short-Acting β-Blocker, ONO-1101

A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more car...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Chemical & pharmaceutical bulletin 1992/06/25, Vol.40(6), pp.1462-1469
Hauptverfasser:	IGUCHI, Sadahiko, IWAMURA, Hiroyuki, NISHIZAKI, Minoru, HAYASHI, Akio, SENOKUCHI, Kazuhiko, KOBAYASHI, Kaoru, SAKAKI, Katsuhito, HACHIYA, Katsutoshi, ICHIOKA, Yumiko, KAWAMURA, Masanori
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-Antagonists - chemical synthesis Adrenergic beta-Antagonists - pharmacology Animals cardioselective Chemistry controllable therapy Dogs emergency treatment Exact sciences and technology Guinea Pigs Heart Atria - drug effects heart disease Heart Rate - drug effects In Vitro Techniques Morpholines - chemical synthesis Morpholines - pharmacology Noncondensed benzenic compounds ONO-1101 Organic chemistry Preparations and properties Structure-Activity Relationship Tachycardia - drug therapy Trachea - drug effects ultra short-acting Urea - analogs & derivatives Urea - chemical synthesis Urea - pharmacology β-blocker
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This β-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.
ISSN:	0009-2363 1347-5223
DOI:	10.1248/cpb.40.1462